Professor of Thoracic Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College & Honorary Consultant Physician at Royal Brompton Hospital, London. Has been the most highly cited clinical scientist in Europe & the most highly cited respiratory researcher in the world over the last 20 years. Elected a Fellow of the Royal Society in 2007. Currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD).
Barnes is the author of over 1,000 publications in peer reviewed journals. He has edited or co-edited over 50 books on asthma, COPD and respiratory pharmacology.
He has been received honorary degrees from the Universities of Ferrara (Italy), Athens (Greece), Tampere (Finland), Leuven (Belgium) and Maastricht (Netherlands). He co-founded an Imperial spin-out company RespiVert, which was acquired by Johnson & Johnson and has developed novel inhaled treatments for COPD and severe asthma.
Professor of Pulmonary Medicine at the Univeristy of Montpellier. Former Director of the INSERM Laboratory for the Immunopathology of Asthma & former chairman of the Global Initiative for Asthma (GINA). Founder & Chairman of ARIA (Allergic Rhinitis & its Impact on Asthma). Chairman of the WHO Global Alliance against Chronic Respiratory Diseases (GARD). Former President of the Societé Française d'Allergologie et d'Immunologie Clinique. Former EiC of the journal Allergy.
Professor and Chairman, Department of Genetic Medicine, and Bruce Webster Professor of Internal Medicine, at Weill Cornell Medical College. Director of the Belfer Gene Therapy Core Facility. Attending Physician at the Weill Cornell-New York Presbyterian Hospital. Previously, Chief of Pulmonary Branch, NHLBI, NIH.
Assistant Professor of Medicine, Division of Pulmonary and Critical Care Medicine, UCLA School of Medicine.
Delia Goletti MD, PhD, Infectious Diseases specialist. In 1992 she joined the Laboratory of Immunoregulation at the National Institutes of Health (chief Dr Fauci) working on HIV pathogenesis. In 1999 she joined the National Institute for Infectious Diseases in Rome. She has clinical duties on the tuberculosis (TB) clinic and responsibility of the Translational Research Unit where she works on TB pathogenesis, TB immunodiagnostic tests and impact of Heminths infection on HIV and TB disease.
I am a biostatistician in the Biostatistics Centre at the University of Otago, a role I have held since 2004. Most of my work involves collaborating on a wide range of research projects in the health sciences, particularly in paediatric obesity, sleep, and physical activity; respiratory epidemiology, mostly asthma and COPD; dentistry; and health systems. I also work on statistical methods research, mostly topics inspired by these collaborations.
Prior to my current position I was a software metrics and machine learning researcher in the Department of Information Science at the same institution.
Dr. Lei Huang is a cancer epidemiologist, translational oncologist, digestive surgeon, surgical oncologist, and gastroenterologist. He has published about 50 papers in SCI(E)-indexed journals including Gut, Annals of Surgery, BMC Medicine, JAMA Surgery, Clinical Cancer Research, Cancer Immunology Research, International Journal of Cancer, EBioMedicine, and Gastric Cancer. His works have been cited for about 1000 times.
Dr. Huang has served on the editorial board of Frontiers in Oncology, World Journal of Gastrointestinal Oncology, PeerJ, Medicine, and Translational Cancer Research, and Frontiers in Surgery. He has been peer reviewer for about 50 SCI(E)-indexed journals including Annals of Internal Medicine, Annals of Surgery, Clinical Cancer Research, Journal of the National Comprehensive Cancer Network-JNCCN, Cancer Letters, Oncoimmunology, and Oncologist. He was selected as Best Reviewer for Annals of Internal Medicine twice in 2017 and 2019.
Dr. Huang has been invited to give oral presentations in the ASCO Annual Meeting and International Gastric Cancer Congress (IGCC), and has received Merit Awards in the ESMO Annual Meeting and Awards for Young Investigators in the IGCC.
His research interests majorly cover the epidemiological, clinical, and translational aspects of digestive cancers. He has successfully coordinated several large international investigations with participants from the US and about 20 European countries.
Keith Klugman, director for pneumonia, leads the Bill & Melinda Gates Foundation’s work to improve the development and delivery of pneumonia vaccines and expand the use of antibiotic treatments and diagnostic tools.
Keith is a leading expert on antibiotic resistance in pneumonia pathogens and helped develop the pneumococcal vaccine that is now part of the immunization regimen for children born in the United States and is being rolled out globally. Keith was the William H. Foege Professor of Global Health and Professor of Epidemiology in the Rollins School of Public Health at Emory University as well as Professor of Medicine in the Division of Infectious Diseases at the Emory School of Medicine. In addition, he still serves as Honorary Professor in the Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand in South Africa.
Keith has chaired or served on numerous expert committees for the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), among other American and international organizations, and has published more than 450 scientific papers on the subjects of pneumonia, meningitis, antimicrobial resistance, and vaccines for bacterial pathogens, which have been cited more than 20,000 times to date. He is currently the President of the International Society for Infectious Diseases.
Keith trained in South Africa and did his post-doctoral research at Rockefeller University in New York.
Main research Interests:
A) Asthma is a major cause of morbidity in the Western world but curative therapies do not exist. Hence, we aim to understand how early life environmental exposures modify lung development development and the risk of developing asthma throughout life. We use animal models of prenatal exposure to tobacco/nicotine products and human samples.
B) The importance of a steady-state balance of resident and non-resident bacterial communities for human health is increasingly appreciated. Yet, factors driving the composition of such microbial communities remain poorly understood. Therefore, we currently investigate the influence of smoke on the structure and functionality of the lung microbiome and its interaction with the lung health.
Currently Funded Projects
2012 – 2016 Chair of COST Action BM1201 “Developmental origins of Chronic Lung Disease” http://www.cost-early-origin-cld.eu/
2013 – 2016 Understanding the role of the lung microbiome for human health and diseases”, HMGU Environmental Health Projects, Co-PI until move to University of Kiel; Project currently continued on a collaborative basis.
Since 2013 – 2018 PI within German Center for Lung Research www.dzl.de
2016 - 2018 Chair of “The lung Microbiota at the Interface between airway epithelium and the environment” funded by the Leibniz Association
Anesthesiology, bronchoscopy, oncology, pulmonary medicine, lung disease
Prof. Marunaka is the Representative Director, Director of Clinical, and Director of Research Institute for Clinical Physiology, Kyoto Industrial Health Association; Professor, Research Center for Drug Discovery and Pharmaceutical Development, Ritsumeikan University; Jinshan Distinguished Professor, International Research Center for Food Nutrition and Safety, Jiangsu University; Professor Emeritus, Kyoto Prefectural University of Medicine; President, Physiological Society of Japan. MD (1979), PhD (1985), Kyoto Prefectural University of Medicine; National License of Physician and Surgeon, Japan (1979). He was Professor and Chairperson, Departments of Molecular Cell Physiology and Bio-Ionomics, Kyoto Prefectural University of Medicine, Japan, and Director and Professor, Japan Institute for Food Education and Health, St. Agnes’ University. He was awarded “Vebleo Nanomedicine Scientist Award” (Sweden), “Marco Polo della Scienza Italiana” (Italy), The Premier's Research Excellence Award (Canada), Scholar Award (Medical Research Council of Canada) and Research Award from National Kidney Foundation of USA. He has obtained more than 60 research grants, published more than 250 peer reviewed articles, and provided more than 30 invited plenary lectures at international congresses and research conferences. h-index 40, i10-index 161, Citation 5714
Professor of Biology at McMaster University, President of the Canadian Society of Zoologists (2019-2020).
My research focuses on the ontogeny, phenotypic plasticity and evolution of muscle metabolism - important for locomotion, thermogenesis, and whole-body metabolic homeostasis. I use mechanistic and evolutionary physiology approaches, and take advantage of "experiments in nature" by studying species that thrive in extreme environments such as high altitude. I do applied research on the impacts of changing temperature, low oxygen, and pollution on the physiology of fishes.